SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Financials Shenzhen New Industries Biomedical Engineering Co., Ltd.
Equities
300832
CNE100003T39
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.15 CNY | +2.56% |
|
+8.46% | -10.29% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 54,455 | 34,652 | 39,416 | 61,443 | 55,118 | - | - |
| Enterprise Value (EV) 1 | 54,455 | 34,652 | 38,934 | 60,397 | 52,840 | 51,665 | 52,987 |
| P/E ratio | 55.5 x | 35.6 x | 29.7 x | 37.2 x | 26.8 x | 21.1 x | 17.1 x |
| Yield | - | 1.36% | 1.4% | 1.28% | 1.78% | 2.23% | 2.59% |
| Capitalization / Revenue | 24.8 x | 13.6 x | 12.9 x | 15.6 x | 11.2 x | 8.86 x | 7.27 x |
| EV / Revenue | 24.8 x | 13.6 x | 12.8 x | 15.4 x | 10.8 x | 8.3 x | 6.99 x |
| EV / EBITDA | 45.8 x | 27.8 x | 26.3 x | 31.3 x | 21.2 x | 16.6 x | 14.1 x |
| EV / FCF | - | - | 69.5 x | 55.1 x | 32.4 x | 26.4 x | 21.1 x |
| FCF Yield | - | - | 1.44% | 1.81% | 3.08% | 3.79% | 4.73% |
| Price to Book | 11.3 x | 6.17 x | 6.16 x | 8.14 x | 6.06 x | 4.95 x | 3.96 x |
| Nbr of stocks (in thousands) | 783,465 | 786,659 | 786,126 | 785,719 | 785,719 | - | - |
| Reference price 2 | 69.51 | 44.05 | 50.14 | 78.20 | 70.15 | 70.15 | 70.15 |
| Announcement Date | 3/30/21 | 4/21/22 | 4/6/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,195 | 2,545 | 3,047 | 3,930 | 4,914 | 6,223 | 7,578 |
| EBITDA 1 | 1,190 | 1,248 | 1,479 | 1,928 | 2,490 | 3,109 | 3,752 |
| EBIT 1 | 1,099 | 1,137 | 1,504 | 1,895 | 2,335 | 2,981 | 3,670 |
| Operating Margin | 50.05% | 44.69% | 49.35% | 48.23% | 47.52% | 47.91% | 48.43% |
| Earnings before Tax (EBT) 1 | 1,097 | 1,136 | 1,501 | 1,893 | 2,361 | 3,004 | 3,688 |
| Net income 1 | 939.1 | 973.7 | 1,328 | 1,654 | 2,059 | 2,616 | 3,216 |
| Net margin | 42.79% | 38.25% | 43.58% | 42.08% | 41.9% | 42.04% | 42.44% |
| EPS 2 | 1.252 | 1.239 | 1.689 | 2.104 | 2.621 | 3.329 | 4.093 |
| Free Cash Flow 1 | - | - | 559.8 | 1,096 | 1,630 | 1,957 | 2,508 |
| FCF margin | - | - | 18.37% | 27.9% | 33.17% | 31.45% | 33.1% |
| FCF Conversion (EBITDA) | - | - | 37.85% | 56.86% | 65.46% | 62.94% | 66.84% |
| FCF Conversion (Net income) | - | - | 42.16% | 66.29% | 79.16% | 74.81% | 77.99% |
| Dividend per Share 2 | - | 0.6000 | 0.7000 | 1.000 | 1.247 | 1.564 | 1.816 |
| Announcement Date | 3/30/21 | 4/21/22 | 4/6/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | - | 989.3 | 1,865 | - | 1,022 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | 459.8 | 865.5 | 501.4 | 528.5 |
| Operating Margin | - | 46.48% | 46.4% | - | 51.73% |
| Earnings before Tax (EBT) 1 | - | 458.8 | 864.3 | 501.3 | 527.5 |
| Net income | 355.1 | 394.9 | 750 | - | - |
| Net margin | - | 39.92% | 40.21% | - | - |
| EPS | 0.4517 | 0.5025 | 0.9542 | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/27/23 | 8/24/23 | 8/24/23 | 10/26/23 | 4/11/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 482 | 1,047 | 2,278 | 3,453 | 2,131 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 560 | 1,096 | 1,630 | 1,957 | 2,508 |
| ROE (net income / shareholders' equity) | 22.4% | 18.9% | 21.9% | 23.7% | 23.1% | 24.2% | 23.6% |
| ROA (Net income/ Total Assets) | 21.4% | 17% | 18.9% | - | 21.3% | 22.4% | 21.1% |
| Assets 1 | 4,382 | 5,721 | 7,015 | - | 9,679 | 11,691 | 15,241 |
| Book Value Per Share 2 | 6.130 | 7.130 | 8.140 | 9.600 | 11.60 | 14.20 | 17.70 |
| Cash Flow per Share 2 | 1.250 | 0.9800 | 1.220 | 1.810 | 2.630 | 3.140 | 3.670 |
| Capex 1 | 253 | 343 | 403 | 322 | 359 | 449 | 657 |
| Capex / Sales | 11.53% | 13.46% | 13.21% | 8.2% | 7.31% | 7.21% | 8.67% |
| Announcement Date | 3/30/21 | 4/21/22 | 4/6/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
70.15
CNY
Average target price
80.56
CNY
Spread / Average Target
+14.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.29% | 7.61B | |
| +0.80% | 12.8B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B | |
| -8.80% | 1.53B |
- Stock Market
- Equities
- 300832 Stock
- Financials Shenzhen New Industries Biomedical Engineering Co., Ltd.
